Clinical EfficacyThe initial results with CLN-049 are highly encouraging, with a differentiated mechanism and potential to treat nearly all AML patients regardless of underlying genetic mutations.
Market OpportunityFL T3 presents several features with the potential to treat a broad AML population with 22k incident patients in the US per year and management seeing a $1b+ opportunity.
Stock PerformanceCullinan shares closed up 17.5% following the positive results, with shares now up over 100% since early October.